NEWSROOM

Get the latest Terumo Aortic news featuring our tailored thoracic,
thoracoabdominal and abdominal devices.

TERUMO AORTIC ANNOUNCES ENROLMENT OF PATIENTS IN AN ALL-COMERS TREO AAA STUDY

Terumo Aortic announced today the enrolment of patients in an all-comers Abdominal Aortic Aneurysm (AAA) Study of the TREO Abdominal Stent-Graft System in the United States. The TREO Abdominal Stent-Graft System is approved by the US Food and Drug Administration (FDA) to treat patients with abdominal aortic aneurysms. This is a prospective, multi-center, non-randomised, single-arm,

TERUMO AORTIC ANNOUNCES US FDA APPROVAL FOR THORAFLEX HYBRID

Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted approval of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for commercial sale in the United States for the treatment of patients with complex aortic arch disease.

TERUMO AORTIC ANNOUNCES US FDA BREAKTHROUGH DEVICE DESIGNATION FOR RELAYBRANCH

Terumo Aortic today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the RelayBranch Thoracic Stent-Graft System. The RelayBranch Thoracic Stent-Graft System is implanted in patients with thoracic aortic arch pathologies requiring treatment that includes coverage of the innominate and left common carotid arteries. The purpose of the FDA’s


1 2 7 8

For more updates on Terumo Aortic, follow us on Twitter or LinkedIn.

MEDIA ENQUIRIES

Please reach out to our media relations contact for
press enquiries about our innovative solutions.


Carrie White
Head, Global Marketing Communications
+44 (0) 141 812 5555